Striatal dopamine release in schizophrenia comorbid with substance dependence

Molecular Psychiatry

Volumn 18, Issue 8, 2013, Pages 909-915

  Thompson, J L ^a   Urban, N ^a   Slifstein, M ^a   Xu, X ^a   Kegeles, L S ^a   Girgis, R R ^a   Beckerman, Y ^a   Harkavy Friedman, J M ^a   Gil, R ^a   Abi Dargham, A ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

alcohol; dopamine; drug dependence; PET; schizophrenia; striatal

Indexed keywords

AMPHETAMINE; DOPAMINE; RACLOPRIDE C 11;

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE RELEASE; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIFORM DISORDER; SUBSTANCE ABUSE;

ADULT; AMPHETAMINE; CASE-CONTROL STUDIES; CORPUS STRIATUM; DIAGNOSIS, DUAL (PSYCHIATRY); DOPAMINE; FEMALE; FUNCTIONAL NEUROIMAGING; HUMANS; MALE; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 84881176306     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.109     Document Type: Article

References (42)

1. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235-9240
2. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry 1998; 155: 761-767
3. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 2569-2574
4. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol Psychiatry 1999; 46: 56-72
5. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, Broft A et al. Amphetamine-induced dopamine release: Markedly blunted in cocaine dependence and predictive of the choice to self-Administer cocaine. Am J Psychiatry 2007; 164: 622-629
6. Martinez D, Gil R, Slifstein M, Hwang DR, Huang Y, Perez A et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 2005; 58: 779-786
7. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997; 386: 830-833
8. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001; 21: 1034-1057
9. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010; 67: 231-239
10. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-2518
11. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv 2006; 57: 1110-1116
12. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM et al. Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 2006; 194: 164-172
13. Swendsen J, Ben-Zeev D, Granholm E. Real-Time electronic ambulatory monitoring of substance use and symptom expression in schizophrenia. Am J Psychiatry 2011; 168: 202-209
14. Cantwell R, Brewin J, Glazebrook C, Dalkin T, Fox R, Medley I et al. Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry 1999; 174: 150-153
15. Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 69-72
16. Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 2007; 190: 515-520
17. Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005; 112: 141-148
18. Verdoux H, Liraud F, Gonzales B, Assens F, Abalan F, van Os J. Suicidality and substance misuse in first-Admitted subjects with psychotic disorder. Acta Psychiatr Scand 1999; 100: 389-395
19. Schiffer B, Muller BW, Scherbaum N, Forsting M, Wiltfang J, Leygraf N et al. Impulsivity-related brain volume deficits in schizophrenia-Addiction comorbidity. Brain 2010; 133: 3093-3103
20. Ebdrup BH, Glenthoj B, Rasmussen H, Aggernaes B, Langkilde AR, Paulson OB et al. Hippocampal and caudate volume reductions in antipsychotic-naive firstepisode schizophrenia. J Psychiatry Neurosci 2010; 35: 95-104
21. Mathalon DH, Pfefferbaum A, Lim KO, Rosenbloom MJ, Sullivan EV. Compounded brain volume deficits in schizophrenia-Alcoholism comorbidity. Arch Gen Psychiatry 2003; 60: 245-252
22. Wobrock T, Sittinger H, Behrendt B, D'Amelio R, Falkai P. Comorbid substance abuse and brain morphology in recent-onset psychosis. Eur Arch Psychiatry Clin Neurosci 2009; 259: 28-36
23. Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R. Diagnosis of comorbid psychiatric disorders in substance users assessed with the psychiatric research interview for substance and mental disorders for DSM-IV. Am J Psychiatry 2006; 163: 689-696
24. Nurnberger Jr JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH genetics initiative. Arch Gen Psychiatry 1994; 51: 849-859
25. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSMIV Axis I Disorders-Non-Patient Edition. New York Biometrics Research: New York State Psychiatric Institute, New York, NY, USA, 1996
26. Hollingshead AB. Four Factor Index of Social Status, Working paper Connecticut, 1975 (Unpublished Working Paper, Department of Sociology, Yale University, New Haven, CT, USA
27. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
28. Watabe H, Endres CJ, Breier A, Schmall B, Eckelman WC, Carson RE. Measurement of dopamine release with continuous infusion of [11C]raclopride: Optimization and signal-To-noise considerations. J Nucl Med 2000; 41: 522-530
29. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23: 285-300
30. van Kammen DP, Murphy DL. Attenuation of the euphoriant and activating effects of d-And l-Amphetamine by lithium carbonate treatment. Psychopharmacologia 1975; 44: 215-224
31. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995; 36: 1182-1190
32. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97: 8104-8109
33. Martinez D, Greene K, Broft A, Kumar D, Liu F, Narendran R et al. Lower level of endogenous dopamine in patients with cocaine dependence: Findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry 2009; 166: 1170-1177
34. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Jayne M et al. Profound decreases in dopamine release in striatum in detoxified alcoholics: Possible orbitofrontal involvement. J Neurosci 2007; 27: 12700-12706
35. Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S et al. Dopamine release in chronic cannabis users: A [(11)C]raclopride positron emission tomography study. Biol Psychiatry 2012; 71: 677-683
36. Fehr C, Yakushev I, Hohmann N, Buchholz HG, Landvogt C, Deckers H et al. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry 2008; 165: 507-514
37. Busto UE, Redden L, Mayberg H, Kapur S, Houle S, Zawertailo LA. Dopaminergic activity in depressed smokers: A positron emission tomography study. Synapse 2009; 63: 681-689
38. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine in drug abuse and addiction: Results of imaging studies and treatment implications. Arch Neurol 2007; 64: 1575-1579
39. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009; 56(Suppl 1): 3-8
40. Michaelides M, Thanos PK, Kim R, Cho J, Ananth M, Wang GJ et al. PET imaging predicts future body weight and cocaine preference. Neuroimage 2012; 59: 1508-1513
41. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: Meta-Analysis of imaging studies. Arch Gen Psychiatry 2012: Doi:10.1001/ archgenpsychiatry.2012.1169
42. Schubert KO, Focking M, Prehn JH, Cotter DR. Hypothesis review: Are clathrinmediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? Mol Psychiatry 2011; 0: 1-13